Imago Biosciences have recently developed inhibitors of the enzyme lysine-specific demethylase 1 (LSD1). This enzyme plays a critical role in regulating the growth and development of bone marrow cells. Their first inhibitor of LSD1 called IMG-7289 is being tested in patients with acute myeloid leukemia, myelodysplastic syndrome, and myelofibrosis.
Imago's efforts are aimed at improving the management of proliferative diseases of the bone marrow and activation of the immune system.
Are you the next big thing?
We’re a team of VC/PE who are excited about innovative ideas in life sciences. Submit your proposal to us!